ClinicalTrials.gg
RecruitingNCT06485947DBPilotUpdated Jul 8, 2025

Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma

A Phase 1 interventional study of Dinutuximab beta and chemotherapy treatment called GPOH in Neuroblastoma, sponsored by Princess Maxima Center for Pediatric Oncology. Recruiting at 1 site in Netherlands. Open to participants aged 18 Months to 18 Years. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Princess Maxima Center for Pediatric Oncology · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Neuroblastoma with a site in Netherlands — 5 open to participants now, 6 under way, 1 of them phase 3. Neuroblastoma · Netherlands.

Planned enrollment
17th of 21
38 · median 115
Started
2025
with 1 other
Phase 1
5 of 23
1 open now
Registered
22nd of 23
by date
Lead sponsor
2 of 23
Princess Maxima Center for Pediatric Oncology

Among the 23 studies in Neuroblastoma with a site in Netherlands, this one is the 17th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 1, and was the 22nd registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

5 of the 23 studies in Neuroblastoma with a site in Netherlands are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: 18 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Neuroblastoma with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this clinical trial is to to assess the dose level of dinutuximab Beta (DB) when combined with 2 different induction chemotherapy regimens (named GPOH or rapid COJEC) in newly diagnosed high-risk neuroblastoma patients. The main question is:

  • to assess the safety and tolerability and identifying the recommended phase II dose and/or the maximum tolerable dose of dinutiximab Beta when combined with 2 standard induction chemotherapy regimens

Participants will receive:

  • GPOH + dinutuximab beta infusion duration = 10 mg/m2 × 5 days (50 mg/m2/course) in 21-day treatment intervals.
  • Rapid COJEC + dinutuximab beta infusion duration = 10 mg/m2 × 3 days (30 mg/m2/course) in 10-day treatment intervals.
Read the detailed description

This study is a multicenter, open-label, dual-cohort, Phase 1 study of DB combined with each of 2 different induction chemotherapy regimens in 2 cohorts. When the recommended cumulative DB dose level has been defined for each of the chemotherapy regimens, a confirmation cohort of 10 evaluable patients per cohort will be enrolled. The maximum number of patients to be enrolled in the dose escalation and dose confirmation parts of the study combined will be 38 evaluable patients for both induction chemotherapy regimens.

For each patient, there will be a screening period of up to 21 days, a treatment period consisting of approximately 126 days (GPOH cohort) or 80 days (rapid COJEC cohort), an end of treatment visit at the end of induction treatment and a post-discontinuation safety visit 30 days after the last administration of DB. Patients will enter the follow up phase after completing the induction treatment. We recommend to follow country/site protocol/guidelines for the management of the patients after the induction treatment (e.g. High Risk-NeuroBLastoma (HR-NBL)-2 study (EudraCT : 2019-001068-31).

There are two study periods:

The first period lasts until the last patient has completed the end of treatment visit. The analysis of these results will answer the primary endpoint of the study. The planned duration for each patient enrolled is approximately 5 months, and the total study duration is approximately 2 years.

The second period lasts until the last patient has completed the follow up. In this period, data for exploratory endpoints are collected. The plan is to report late toxicity (mainly related to the high-dose chemotherapy) when the last patient completed the end of study visit and in a further report the results of 3 and 5 years follow up.

03

Conditions studied

  • Neuroblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Established diagnosis of neuroblastoma Stage M, according to the SIOPEN modified International Neuroblastoma Risk Group (INRG) and to the INSS criteria (Appendix 1).
  2. Age ≥18 months and \<18 years.
  3. Body weight >12 kg.
  4. and aspartate aminotransferase \<10 × (ULN), total \<1.5 × ULN based on age specific reference ranges.
  5. Calculated > 60 mL/min/1.73 m2 or serum creatinine \<1.5 × ULN corrected for age.
  6. Shortening fraction (SF) ≥27% and/or (LVEF) >50% as determined by echocardiography or MUGA.
  7. Able to comply with scheduled follow-up and study procedures.
  8. Written from parents/legal representative, patient, and age-appropriate assent before any study specific screening procedures are conducted, according to local, regional or national law and legislation.

Exclusion criteria

Exclusion Criteria:

  1. Previous cancer-specific treatment for neuroblastoma.
  2. Current use of a prohibited medication or requires any of these medications during the study:

    1. Treatment with is not allowed within 2 weeks prior to the first block of chemotherapy and until 1 week after the last treatment course with dinutuximab beta, except for life-threatening conditions.
    2. Vaccinations (including seasonal influenza) are not allowed during administration of dinutuximab beta and until 10 weeks after last treatment course.
    3. Concomitant use of intravenous (IV) immunoglobulins is not allowed.
    4. Concomitant use of cardioprotectant dexrazoxane is not allowed.
  3. Pregnancy or positive pregnancy test in females of .
  4. Breast feeding.
  5. Sexually active participants not willing to use highly effective method
  6. Major surgery within 21 days prior to the first treatment dose
  7. History or documented evidence of severe acute or chronic infection or infectious illness requiring parenteral therapy unless fully healed
  8. Patients with spinal cord involvement
  9. Any other disease, metabolic or psychological dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an drug
  10. Have a known immediate or delayed reaction to study drugs
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Dinutuximab Beta with chemotherapy treatment called GPOH

    Dinutuximab Beta will be administered at a fixed daily dose of 10 mg/m2 given as a 24-hour continuous infusion for a scheduled number of days within each treatment cycle of chemotherapy.

    Biological: Dinutuximab beta · Drug: chemotherapy treatment called GPOH

  • Experimental
    Dinutuximab Beta with chemotherapy treatment called rapid COJEC

    Dinutuximab Beta will be administered at a fixed daily dose of 10 mg/m2 given as a 24-hour continuous infusion for a scheduled number of days within each treatment cycle of chemotherapy.

    Biological: Dinutuximab beta · Drug: chemotherapy treatment called rapid COJEC

Interventions

  • BiologicalDinutuximabStudies of DinutuximabDinutuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Combination of immunotherapy with standard chemotherapy

    Also known as: Immunotherapy

  • Drugchemotherapy treatment called GPOH

    chemotherapy treatment called GPOH

  • Drugchemotherapy treatment called rapid COJEC

    chemotherapy treatment called rapid COJEC

06

What researchers measure

Primary outcomes

  1. the incidence of dose limiting toxicities (DLTs) associated with the combination of Dinituximab Beta with GPOH chemotherapy regimen

    Number of DLT's per dose level of Dinituximab Beta

    Time frame: Within first 63 days of treatment

  2. the incidence of dose limiting toxicities (DLTs) associated with the combination of Dinituximab Beta with rapid COJEC chemotherapy regimen

    Number of DLT's per dose level of Dinituximab Beta

    Time frame: Within first 50 days of treatment

Secondary outcomes

  1. overall response rate during after Dinituximab Beta with GPOH chemotherapy regimen

    Tumor imaging

    Time frame: 126 days

  2. metastatic response rate after Dinituximab Beta with GPOH chemotherapy regimen

    Tumor imaging

    Time frame: 126 days

  3. overall response rate during after Dinituximab Beta with rapid COJEC chemotherapy regimen

    Tumor imaging

    Time frame: 80 days

  4. metastatic response rate after Dinituximab Beta with rapid COJEC chemotherapy regimen

    Tumor imaging

    Time frame: 80 days

Other outcomes

  1. event free survival (EFS) from the date of enrollment

    exploratory endpoints

    Time frame: 5 years

  2. overall survival (OS) from the date of enrollment

    exploratory endpoints

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication (CSR)

Supporting information: Clinical study report

Time frame: Within 6 months from study end.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jul 2030, 65 months after the start.

Of 73 non-industry phase 1 interventional studies under Neuroblastoma, half reached primary completion within 89 months of starting (the median), counting those still running; a quarter within 65 and three quarters within 117. This study's planned 65 months is below that.

Counting every sponsor, half of 86 studies reached it within 83 months; a quarter within 60 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Jul 3, 2024
StartActual
Jan 28, 2025
Primary completionEst.
Jul 1, 2030
CompletionEst.
Dec 1, 2031
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06485947
Lead sponsor
Princess Maxima Center for Pediatric Oncology
Collaborators
EUSA Pharma, Inc.
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Jan 28, 2025
Primary completion
Jul 1, 2030 (estimated)
Completion
Dec 1, 2031 (estimated)
Last update
Jul 8, 2025

Study contacts

Jorden Veeneman, PhD
Contact
trialmanagement@prinsesmaximacentrum.nl
+31650173417
Paco Bautista, MD, PhD
Contact
f.j.bautista@prinsesmaximacentrum.nl
0031650006606
Holger Lode, MD, PhD
principal investigator · Princess Maxima Center for Pediatric Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion